<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01045122</url>
  </required_header>
  <id_info>
    <org_study_id>Sleep Study CReFF award</org_study_id>
    <secondary_id>5M01RR000044</secondary_id>
    <nct_id>NCT01045122</nct_id>
  </id_info>
  <brief_title>Sedation in Patients at Risk for Upper Airway Collapse</brief_title>
  <official_title>Sedation in Patients at Risk for Sleep-induced Upper Airway Collapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Overview of Protocol:

      Between Subject - Repeated Measures design will be used to assess the airway response of two
      groups of subjects under two different sedated conditions. Each group will be comprised of
      six subjects and will be categorized according to their baseline profile for risk for SDB (&lt;
      10 RDI or &gt; 25 RDI). Some subjects will have been prescribed continuous positive airway
      pressure (CPAP) therapy by their treating physician as a result of their overnight sleep
      study. CPAP treatment is effective in splinting the airway open and thus decreasing the
      incident of airway collapse during sleep. Thus, CPAP utilization will also be tracked as an
      independent and continuous variable as regular CPAP use has been found to be associated with
      increased resistance to UAC (upper airway collapse).

      The experimental conditions will evaluate upper airway patency and instability in response to
      two forms of intravenous sedation: propofol and dexmedetomidine.

      Subjects will be continuously monitored during each experimental condition for respiratory
      effort and flow, and for EEG, EMG, and ECG.

      Respiratory instability will first be assessed while subjects are under sedation without any
      airway provocation. The degree of respiratory instability will be quantified in terms of the
      following measurements: a modified Respiratory Disturbance Index (RDIsedated), respiratory
      arousals, and minute ventilation. The apneic periods will be classified by their mixture of
      central and obstructive components.All outcome measurements are assessed over the period of
      sedation which last for approximately one hour.

      Upper airway patency will be quantified in terms of the critical pharyngeal pressure (Pcrit)
      (the pressure beyond which complete upper airway collapse occurs, see background).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The propensity to experience sleep disordered-breathing (SDB) is controlled by the interplay
      of anatomic factors (i.e. BMI, neck circumference, retrognathia) and neurological drive
      (sleep stage, arousal). The interaction of baseline anatomic factors and drug-induced altered
      neurologic drive may also convey a risk for upper airway collapse (UAC) in patients receiving
      analgesics, or sedation/anesthesia.1;2 While there is mainly only anecdotal evidence to
      support the proposition that SDB is a strong predictor of sedation-related adverse events,3;4
      there is such a remarkable consensus of opinion regarding this association that, for example,
      the American Society of Anesthesiologists is developing guidelines to specifically address
      the issue of managing this group of &quot;at risk&quot; patients who are to undergo sedation or
      anesthesia. SDB is a term that is used to describe a spectrum of sleep-related breathing
      disturbances. Obstructive Sleep Apnea (OSA) is a condition that incorporates SDB with daytime
      symptoms (i.e. hypersomnolence). These terms are commonly used interchangeably.

      At this juncture, what is needed are clear demonstrations: 1) that SDB confers risk for
      sedation-related adverse events (epidemiologically and/or experimentally), 2) of the patient
      and drug factors that moderate/mediate the risk, and 3) of the mechanisms responsible for the
      patient by drug interactions.

      This proposed project will, in a preliminary way, address the first and second of these
      issues. Specifically, the upper airway characteristics of patients with different severity
      classifications of SDB will be assessed while under the influence of two,
      neuropharmacologically distinct, intravenous sedatives.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory Disturbance Index</measure>
    <time_frame>during infusion of study drugs</time_frame>
    <description>respiratory events (apneas, hypopneas) per hour</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with mild or no Sleep disorder breathing

          -  Patients with moderate to severe Sleep disorder breathing

        Exclusion Criteria:

          -  No unstable medical conditions

          -  Anatomic pathology of airway

          -  Pregnancy or nursing

          -  Inability to fit an anesthesia facemask

          -  Excessive alcohol or drug abuse

          -  Bleeding abnormalities

          -  Claustrophobia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suzanne B Karan, Medical</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Denham Ward, Medical</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2010</study_first_posted>
  <results_first_submitted>April 7, 2014</results_first_submitted>
  <results_first_submitted_qc>April 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 27, 2015</results_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Suzanne Karan</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Obstructive Sleep Apnea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment April 2006 to November 2008. Subjects were recruited from advertisements, patient letters sent out through the strong sleep center.</recruitment_details>
      <pre_assignment_details>Subjects excluded from trial before assignment to group because Prior airway surgery, unstable medical conditions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Propofol First</title>
          <description>Propofol was administered first in 5/11 subjects with a one week washout at least between the next run with dexmedetomidine</description>
        </group>
        <group group_id="P2">
          <title>Dexmedetomidine First</title>
          <description>Dexmedetomidine was administered on the first day in 6/11 subjects with at least a one week washout between runs before the subjects underwent the experiment with propofol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dexmedetomidine Then Propofol</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Propofol Then Dexmedetomidine</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Propofol vs Dexmedetomidine</title>
          <description>We aim to study two commonly used sedatives (propofol vs dexmedetomidine) in subjects with OSA for their propensity to produce sedation related respiratory events</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Respiratory Disturbance Index</title>
          <description>The Degree of respiratory instability will be quantified in terms of the following measurements: a Respiratory Disturbance Index in events per hour.</description>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.99" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Disturbance Index</title>
        <description>respiratory events (apneas, hypopneas) per hour</description>
        <time_frame>during infusion of study drugs</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Propofol</title>
            <description>The respiratory disturbance index and airway closing pressures (Pcrit) were quantified for both arms</description>
          </group>
          <group group_id="O2">
            <title>Dexmedetomidine</title>
            <description>The respiratory disturbance index and airway closing pressures (Pcrit) were quantified for both arms</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Disturbance Index</title>
          <description>respiratory events (apneas, hypopneas) per hour</description>
          <population>Per protocol</population>
          <units>events per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.52" spread="165.6"/>
                    <measurement group_id="O2" value="21.32" spread="39.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Propofol</title>
          <description>Is an alkylphenol, is primarily indicated for use as a general anesthetic and has minimal analgesic properties.
Propofol: For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.</description>
        </group>
        <group group_id="E2">
          <title>Dexmedetomidine</title>
          <description>Dexmedetomidine is an alpha-2 adrenoreceptor agonist that has sedative, hypnotic, and analgesic effects.
Dexmedetomidine: For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Suzanne Karan</name_or_title>
      <organization>University of Rochester Medical Center</organization>
      <phone>585-275-5161</phone>
      <email>Suzanne_Karan@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

